mTOR as a target for cancer therapy

Curr Top Microbiol Immunol. 2004;279:339-59. doi: 10.1007/978-3-642-18930-2_20.

Abstract

The target of rapamycin, mTOR, acts as a sensor for mitogenic stimuli, such as insulin-like growth factors and cellular nutritional status, regulating cellular growth and division. As many tumors are driven by autocrine or paracrine growth through the type-I insulin-like growth factor receptor, mTOR is potentially an attractive target for molecular-targeted treatment. Further, a rationale for anticipating tumor-selective activity based on transforming events frequently identified in malignant disease is becoming established.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / antagonists & inhibitors
  • Antibiotics, Antineoplastic / pharmacology*
  • Antibiotics, Antineoplastic / therapeutic use
  • Apoptosis / drug effects
  • Child
  • Clinical Trials as Topic
  • Humans
  • Insulin-Like Growth Factor I / pharmacology
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology
  • Protein Kinases / metabolism*
  • Receptor, Insulin / metabolism
  • Rhabdomyosarcoma, Alveolar / drug therapy
  • Rhabdomyosarcoma, Alveolar / enzymology
  • Sirolimus / antagonists & inhibitors
  • Sirolimus / pharmacology*
  • Sirolimus / therapeutic use
  • TOR Serine-Threonine Kinases
  • Tumor Cells, Cultured

Substances

  • Antibiotics, Antineoplastic
  • Insulin-Like Growth Factor I
  • Protein Kinases
  • MTOR protein, human
  • Receptor, Insulin
  • TOR Serine-Threonine Kinases
  • Sirolimus